As per the exchange filing, Biocon Biologics will take responsibility across the product lifecycle, which includes ...

As part of this announcement, Biocon's board has also approved raising funds to the tune of ₹4,500 crore through a Qualified Institutional Placement.

Indian pharmaceuticals firm Biocon Ltd. will buy out minority shareholders in Biocon Biologics Ltd. via a mix of cash and shares in a deal that values the biosimilars unit at $5.5 billion.

Biocon Biologics has gained complete global rights for Hulio, a biosimilar Adalimumab. This move grants Biocon Biologics full ...

Ajanta Pharma has signed an in-licensing pact with Biocon to commercialise semaglutide in 26 countries across Africa, the ...

Biocon Biologics Ltd obtains full exclusive global rights for Hulio, a biosimilar Adalimumab, from Fujifilm Kyowa Kirin ...

Viatris is letting go of the equity stake it’s held in Biocon’s biosimilar subsidiary Biocon Biologics for $815 million, allowing Biocon to fully integrate its subsidiary. | Returning its stake in ...

Ajanta Pharma secures exclusive rights to market Biocon's semaglutide in 26 countries, targeting growth in diabetes and ...

Under the agreement, Biocon will supply semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive ...

The Biocon board cleared the issuance of 17.1 crore new shares to Biocon Biologics’ minority shareholders at Rs 405.6 per share, a 3.3 per cent premium to Biocon’s closing price on Friday.

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market ...

Rajesh Palviya of Axis Securities advises buying Biocon with a stop loss at Rs 395 and a target of Rs 414. Out of 18 analysts tracking the company, 11 maintain a 'buy' rating, two recommend a 'hold,' ...